Economics
China Probes 60 Drugmakers in Effort to Curb Drug Prices
This article is for subscribers only.
China’s top economic planning agency is investigating the costs and prices of drugmakers including GlaxoSmithKline Plc, Merck & Co., Novartis AG and Baxter International Inc. to improve the pricing system for medicines.
The National Development and Reform Commission will examine 27 companies for costs and 33 for pricing, according to a July 2 statement posted on the commission’s Evaluation Center of Drug Pricing. The investigation is being done so that drug prices can be adjusted in a more timely fashion, it said.